内脏脂肪反映强直性脊柱炎患者的疾病活动情况。

Visceral fat reflects disease activity in patients with ankylosing spondylitis.

作者信息

Aydin Mesut, Aydin Fatma, Yuksel Murat, Yildiz Abdulkadir, Polat Nihat, Akil Mehmet A, Bilik Mehmet Z, Akyuz Abdurrahman, Batmaz Ibrahim, Alan Sait

机构信息

出版信息

Clin Invest Med. 2014 Jun 1;37(3):E186. doi: 10.25011/cim.v37i3.21385.

DOI:10.25011/cim.v37i3.21385

PMID:24895992

Abstract

PURPOSE

Response to infliximab treatment diminishes as body mass index (BMI) increases in patients with ankylosing spondylitis (AS). The purpose of the study was to determine if diminished response to infliximab treatment in patients with AS could be associated with increased visceral adipose tissue rather than increased BMI.

METHODS

Twenty six AS patients (21 males and five females) who fulfilled the modified New York criteria and who were currently receiving infliximab treatment were enrolled in the study. Pain was measured by the visual analogue scale (VAS). The disease activity and functional status were assessed by the Bath AS Disease Activity Index (BASDAI) and the Bath AS Functional Index (BASFI). The Bath AS Metrology Index (BASMI) was used to evaluate mobility restrictions. Weight and visceral body composition were measured without shoes in light indoor clothes using a bio-impedance meter.

RESULTS

There was a significant correlation between visceral adipose tissue amount and disease activity under infliximab treatment. In correlation analysis, visceral fat showed significant correlations between BASDAI (r=0.545, p=0.004) and VAS (r=0.458, p=0.019). Total body fat also showed a significant correlation with BASDAI (r=0.463, p=0.017).

CONCLUSION

A significant correlation was found between visceral adipose tissue amount and disease activity in patients with AS.

摘要

目的

在强直性脊柱炎（AS）患者中，随着体重指数（BMI）的增加，对英夫利昔单抗治疗的反应会减弱。本研究的目的是确定AS患者对英夫利昔单抗治疗反应减弱是否与内脏脂肪组织增加而非BMI增加有关。

方法

本研究纳入了26例符合修订的纽约标准且正在接受英夫利昔单抗治疗的AS患者（21例男性和5例女性）。疼痛采用视觉模拟量表（VAS）进行测量。疾病活动度和功能状态通过巴斯强直性脊柱炎疾病活动指数（BASDAI）和巴斯强直性脊柱炎功能指数（BASFI）进行评估。巴斯强直性脊柱炎计量指数（BASMI）用于评估活动受限情况。使用生物阻抗仪在室内穿着轻便衣物且不穿鞋的情况下测量体重和内脏身体成分。

结果

在英夫利昔单抗治疗下，内脏脂肪组织量与疾病活动度之间存在显著相关性。在相关性分析中，内脏脂肪与BASDAI（r = 0.545，p = 0.004）和VAS（r = 0.458，p = 0.019）之间显示出显著相关性。全身脂肪与BASDAI也显示出显著相关性（r = 0.463，p = 0.017）。